NZ530154A

NZ530154A - Naphthothiazine positive allosteric AMPA receptor modulators ( PAARM )

Info

Publication number: NZ530154A
Application number: NZ530154A
Authority: NZ
Inventors: Angelo Ceci; Klaus Klinder; Thomas Weiser; Karin Winter
Original assignee: Boehringer Ingelheim Pharma
Priority date: 2001-05-17
Filing date: 2002-05-15
Publication date: 2005-09-30
Also published as: PL364053A1; DE10123952A1; EA200301167A1; MXPA03010373A; NO20035088L; CA2449189A1; KR20040007572A; CO5550460A2; EP1404340A1; EA006608B1; HUP0401273A3; UY27290A1; BG108324A; ECSP034852A; IL158642A0; WO2002100411A1; CN1533278A; NO20035088D0; CZ20033112A3; ZA200308466B

Abstract

Naphth(1,8-de)-2,3-dihydro-1,2-thiazine derivatives of formula (I) and their enantiomers, diastereomers and salts are disclosed, wherein: R1 can be H, C1-C6 alkyl (optionally substituted by 1 or more halogen atoms), SO2H, C1-C6 alkyl-sulfinyl or -sulfonyl, C1-C6 alkylcarbonyl, O, C1-C4 alkyl substituted by phenyl, NR6R7 or C1-C4 alkoxy, or 3-6C cycloalkyl; R2, R3 (independently) may be H, C1-C6 alkyl (optionally substituted by 1 or more halo), halo, SO2H, C1-C6 alkyl-sulfinyl or -sulfonyl, C1-C6 alkylcarbonyl, OH, C1-C6 alkoxy or alkylthio, C1-C4 alkyl substituted NR<6>R<7> or C1-C4 alkoxy, or 3-6C cycloalkyl; or R1 and R2 together are a C4-C6 alkylene bridge; R6, R7 are independently selected from H, C1-C4 alkyl or C1-C4 alkylcarbonyl; R4, R5 are independently selected from C1-C6 alkyl (optionally substituted with 1 or more halo), phenyl(C1-C4)alkyl, halo, CN, NO2, SO2H, SO3H, C1-C6 alkyl-sulfinyl, C1-C6 alkyl-sulfonyl, SO2NR6R7, carboxy, C1-C6 alkylcarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkocycarbonyl, C1-C4 alkoxycarbonyloxy, CON R6R7, OH, C1-C6 alkoxy, C1-C6 alkylthio, NR6R7, or aryl (optionally substituted by one or more halo, NO2, SO2H or C1-C4 alkyl); and N and m are independently 0-3; provided that naptho(1,8-de)-2,3-dihydro-1,2-thiazine-1,1-dioxide is excluded. Such compositions are useful as pharmaceuticals, particularly for the treatment of neurodegenerative diseases and/or cerebral ischemia, such as schizophrenia, memory disorders and dementias.

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number 530154 WO 02/100411 PCT/EP02/05338 530154 NAPHTHOTHIAZINE POSITIVE ALLOSTERIC AMPA RECEPTOR MODULATORS (PAARM) The present invention relates to new positive allosteric AMPA receptor modulators, processes for preparing them and their use as pharmaceutical compositions. 5 As compounds which are structurally similar to the compounds according to the invention, WO 9967242 describes carbapenem derivatives with an antibacterial activity, wherein naphtho[1,8-de]-2,3-dihydro-1,1-dioxide-1,2-thiazine is used as a synthesis component. 10 The compounds according to the invention are compounds of general formula (I) (I) 15 wherein R1 denotes a group selected from among hydrogen, a Ci-C6-alkyl group optionally substituted by one or more halogen atoms, -SO2H, -S02-Ci-C6-alkyl, 20 -SO-CrC6-alkyl, -CO-Ci-C6-alkyl, -O, phenyl-Ci-C4-alkyl, -Ci-C4-alkyl-NR6R7 and -Ci-C4-alkyl-0- Ci-C4-alkyl, and C3-C6-cycloalkyl, R2, R3, which may be identical or different, denote a group selected from among hydrogen, a Ci-C6-alkyl group optionally substituted by one or more halogen atoms, halogen, -NO2, -SO2H, -S02-Ci-C6-alkyl, -SO-Ci-C6-alkyl, -CO-25 Ci-C6-alkyl, -OH, -0-Ci-C6-alkyl, -S-Ci-C6-alkyl, -Ci-C4-alkyl-NR6R7 and -C1-C4 -alkyl-O- CrC4-alkyl and C3-C6-cycloalkyl, or R1 and R2 together denote a C4-C6-alkylene bridge, 2 0 jul 2005 received WO 02/100411 PCT/EP02/05338 2 R6, R7, which may be identical or different, denote hydrogen, Ci-C4-alkyl or -CO-Ci-C4-alkyl, R8, R9, which may be identical or different, denote hydrogen or CrC4-alkyl, R4 , which may be identical or different, denotes a group selected from among a CrC6-alkyl group optionally substituted by one or more halogen atoms, phenyl-CrC4-alkyl, halogen, -CN, -N02, -S02H, -S03H, -S02-Ci-C6-alkyl, -SO-Ci-C6-alkyl, -S02-NR6R7, -COOH, -CO-CrC6-alkyl, -0-C0-Ci-C4-alkyl, -CO-O-CrC4-alkyl, -0-C0-0-CrC4-alkyl, -CO-NR6R7, -OH, -O-C^Ce-alkyl, -S-C,-C6-alkyl, -NRSR7 and an aryl group optionally mono or polysubstituted by halogen atoms, -N02, -S02H or Ci-C4-alkyl, R5, which may be identical or different, denotes a group selected from among a Ci-C6-alkyl group optionally substituted by one or more halogen atoms, phenyl-Ci-C4-alkyl, halogen, -CN, -NO2, -S02H, -S03H, -S02-C,-C6-alkyl, -SO- Ci-C6-alkyl, -S02-NRBR7, -COOH, -CO-C^Ce-alkyl, -0-C0-CrC4-alkyl, -CO-O- CrC4-alkyl, -0-C0-0-CrC4-alkyl, -CO-NR6R7, -OH, -0-Ci-C6-alkyl, -S-CrCe- alkyl, -NR6R7 and an aryl group optionally mono or polysubstituted by halogen atoms, -N02, -S02H or Ci-C4-alkyl, and n, m which may be identical or different represent 0,1,2 or 3, with the proviso that naphtho[1,8-de]-2,3-dihydro-1,1-dioxide-1,2-thiazine is excluded, optionally in the form of their various enantiomers and diastereomers, and the pharmacologically acceptable salts thereof. Preferred compounds are the compounds of general formula (I), wherein R1 denotes a group selected from among hydrogen, a CrC6-alkyl group optionally substituted by one or more halogen atoms, -S02H, -S02-CrC6-alkyl, -SO-CrC6-alkyl, -CO-Ci-C6-alkyl, -0, -Ci-C4-alkyl-NR7R8 and -CrC4-alkyl-0-Ci-C4 —alkyl, benzyl, R2, R3, which may be identical or different, denote a group selected from among hydrogen, a Ci-Ce-alkyl group optionally substituted by one or more halogen atoms, halogen, -N02, -S02H, -S02-Ci-C6-alkyl, -SO-CrCe-alkyf, -CO- WO 02/100411 PCT/EP02/05338 3 C,-C6-alkyl, -OH, -0-Ci-C6-aIkyl, -S-Ci-C6-alkyl, -Ci-C4-alkyl-NR6R7 and -C1-C4 -alkyl-O- CrC4-alkyl, or R1 and R2 together denote a C4-Ce-alkylene bridge, R6, R7, which may be identical or different, denote hydrogen, CrC4-alkyl or 5 -CO-C1-C2-alkyl, and R4, which may be identical or different, denotes a group selected from among a CrCs-alkyl group optionally substituted by one or more halogen atoms, halogen, -CN, -N02, -S02H, -S03H, -COOH, -CO-Ci-C6-alkyl, -0-C0-Ci-C4-10 alkyl, -C0-0-Ci-C4-alkyl, -0-C0-0-Ci-C4-alkyl, -CO-NR®R7, -OH, -O-C^Cs-alkyl, -S-CrCe-alkyl and -NRSR7, R5, which may be identical or different, denotes a group selected from among a CrC6-alkyl group optionally substituted by one or more halogen atoms, halogen, -CN, -N02, -S02H, -S03H, -COOH, -CO-Ci-C6-alkyl, -0-C0-Ci-C4-15 alkyl, -C0-0-Ci-C4-alkyl, -0-C0-0-CrC4-alkyl, -CO-NR6R7, -OH, -0-CrC6-alkyl, -S-Ci-C6-alkyl and -NRSR7, and n, m which may be identical or different represent 0,1 or 2, optionally in the form of the various enantiomers and diastereomers thereof, as 20 well as the pharmacologically acceptable salts thereof. Particularly preferred are compounds of general formula (I), wherein R1 denotes hydrogen, CrC4-alkyl or benzyl, R2, R3 which may be identical or different, denote hydrogen or CrC4-alkyl, or 25 R1 and R2 together denote a butylene bridge, and R4, which may be identical or different, denotes a group selected from among a Ci-C6-alkyl group optionally substituted by one or more halogen atoms, halogen, -CN, -N02, -COOH, -CO-Ci-C6-alkyl, -0-C0-CrC4-alkyl, -CO-O-Cr C4-alkyl, -0-C0-0-Ci-C4-alkyl, -CO-NR6R7, -OH, -0-CrC6-alkyl, -S-Ci-C6-alkyl 30 and -NReR7, R5, which may be identical or different, denotes a group selected from among a Ci-Ce-aikyl group optionally substituted by one or more halogen atoms, WO 02/100411 PCT/EP02/05338 4 halogen, -CN, -N02, -COOH, -CO-CrC6-alkyl, -0-C0-CrC4-alkyl, -CO-O-C,-C4-alkyl, -0-C0-0-C,-C4-alkyl, -CO-NReR7, -OH, -0-Ci-C6-alkyl, -S-C,-C6-alkyl and -NR6R7, and n, m which may be identical or different represent 0,1 or 2, 5 optionally in the form of the various enantiomers and diastereomers thereof, as well as the pharmacologically acceptable salts thereof. Also particularly preferred are compounds of general formula (I), wherein 10 R1, R2, R3, which may be identical or different, denote hydrogen or Ci-C4-alkyl, R4, which may be identical or different, denotes a group selected from among a CrC6-alkyl group optionally substituted by one or more halogen atoms, halogen, -N02, -0-C0-Ci-C4-alkyl, -0-C0-0-CrC4-alkyl, -0-CrC6-alkyl, and -NReR7, 15 Rs, which may be identical or different, denotes a group selected from among a CrCe-alkyl group optionally substituted by one or more halogen atoms, halogen, -N02, -0-C0-CrC4-alkyl, -0-CO-0-Ci-C4-alkyl, -0-Ci-C6-alkyl, and -NR6R7, and n, m which may be identical or different represent 0,1 or 2, 20 optionally in the form of the various enantiomers and diastereomers thereof, as well as the pharmacologically acceptable salts thereof. Of particular importance according to the invention are the compounds of 25 general formula (I), wherein R1 denotes methyl, ethyl, i-propyl, n-butyl or benzyl, optionally in the form of the various enantiomers and diastereomers thereof, as well as the pharmacologically acceptable salts thereof. 30 Particularly preferred are compounds of general formula (I) wherein R1 denotes methyl, optionally in the form of the pharmacologically acceptable salts thereof. WO 02/100411 5 PCT/EP02/05338 Also particularly preferred are compounds of general formula (I), wherein R1 denotes methyl, R2, R3 denote hydrogen, 5 R4, R5, which may be identical or different, denote halogen, preferably fluorine, chlorine, bromine, most preferably fluorine or chlorine, and n, m which may be identical or different represent 0,1 or 2, preferably 0 or 1, optionally in the form of the pharmacologically acceptable salts thereof. 10 The alkyl groups used, unless otherwise stated, are branched and unbranched alkyl groups having 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms. Examples include: methyl, ethyl, propyl, butyl, pentyl and hexyl. The groups methyl, ethyl, propyl or butyl may optionally also be referred to by the abbreviations Me, Et, Pr or 15 Bu. Unless otherwise stated, the definitions propyl, butyl, pentyl and hexyl also include all possible isomeric forms of the groups in question. Thus, for example, propyl includes n-propyl and iso-propyl, butyl includes iso-butyl, sec. butyl and tert.-butyl, etc. 20 In the abovementioned alkyl groups, one or more hydrogen atoms may optionally be substituted by the halogen atoms fluorine, chlorine, bromine or iodine. The substituents fluorine and chlorine are preferred. The substituent fluorine is particularly preferred. If desired, all the hydrogen atoms of the alkyl group may be replaced. 25 The alkyl group mentioned in the group phenyl-Ci-C4-alkyl may be in branched or unbranched form. Unless otherwise stated benzyl and phenylethyl are preferred phenyl-CrC4-alkyl groups. Benzyl is particularly preferred. 30 The alkyl groups mentioned in the groups -S02-Ci-C6-alkyl, -SO-CrC6-alkyl, -CO-Ci-C6-alkyl, -CO-Ci-C4-alkyl, -Ci-C4-alkyl-NR R , -Ci-C4—alkyl-O- Ci-C4—alkyl, -0-CrCe-alkyl, -S-CrC6-alkyl, -0-C0-Ci-C4-alkyl, -C0-0-CrC4-alkyl or -0-C0-0-Ci-C4- WO 02/100411 PCT/EP02/05338 alkyl may be in branched or unbranched form with 1 to 6 carbon atoms, preferably with 1 to 4 carbon atoms, particularly preferably with 1 to 3 carbon atoms, most preferably with 1 to 2 carbon atoms. 5 The C4-C6-alkylene bridge may, unless otherwise stated, be branched and unbranched alkylene groups having 4 to 6 carbon atoms, for example n-butylene, 1-methylpropylene, 2-methylpropylene, 1.1-dimethylethylene, 1,2-dimethylethylene etc. n-Butylene bridges are particularly preferred. 10 The aryl group is an aromatic ring system having 6 to 10 carbon atoms, preferably phenyl. In the abovementioned aryl groups, one or more hydrogen atoms may optionally be substituted by halogen atoms, -N02, -S02H or -Ci-C4-alkyl, preferably fluorine, chlorine , -N02, ethyl or methyl, most preferably fluorine or methyl. 15 The term C3-C6-cycloalkyl denotes saturated cyclic hydrocarbon groups having 3 - 6 carbon atoms, for example cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. The term halogen, unless otherwise stated, refers to fluorine, chlorine, bromine and 20 iodine, preferably fluorine, chlorine and bromine, most preferably fluorine and chlorine, most preferably fluorine. As already mentioned, the compounds of formula (I) or the various enantiomers and diastereomers thereof may be converted into the salts thereof, particularly, for 25 pharmaceutical use, into the physiologically and pharmacologically acceptable salts thereof. These salts may on the one hand take the form of physiologically and pharmacologically acceptable acid addition salts of the compounds of formula (I) with inorganic or organic acids. On the other hand, the compound of formula (I) where R1 is hydrogen may be converted by reaction with inorganic bases into 30 physiologically and pharmacologically acceptable salts with alkali or alkaline earth metal cations as counter-ions. The acid addition salts may be prepared, for example, using hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, WO 02/100411 PCT/EP02/05338 7 methariesuiphonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid. It is also possible to use mixtures of the above acids. For preparing the alkali and alkaline earth metal salts of the compound of formula (I) wherein R1 denotes hydrogen, it is preferable to use the alkali and 5 alkaline earth metal hydroxides and hydrides, the hydroxides and hydrides of the alkali metals, especially sodium and potassium, being preferred, while sodium and potassium hydroxide are particularly preferred. The compounds according to the invention may be prepared in a manner known per 10 se. The following general methods of synthesis 1 and 2 shown in Diagrams 1 and 2 below are meant to illustrate the invention without restricting it to their content. Method 1 Diagram 1 15 S02CI (II) (III) (IV) (I) WO 02/100411 PCT/EP02/05338 8 Starting from a compound of formula (II) a compound of formula (III) is prepared by sulphonation and subsequent chlorination. The compound of formula (IV) obtained after condensation with aminoacetic acid derivatives is cyclised by adding 5 polyphosphoric acid to the target compound (I). The general preparation of the compounds according to the invention in accordance with Diagram 1 is described in detail hereinafter. 10 Sulphonation of the naphthalenes HIV About 10 mmol of the naphthalene derivative (II) are taken up in 2 -100 ml, preferably 3-80 ml, most preferably about 4 ml, of acetic anhydride and 10-100 mmol, preferably 11 - 80 mmol, particularly preferably 11 mmol or conc. sulphuric acid are added at 0 - 50°C, preferably 5 - 20°C, particularly preferably about 18 °C. 15 After 2 -16 h, preferably about 5 h, stirring at 20 - 100°C, preferably about 25 C°, the mixture is poured onto a saturated NaCI solution. The crystals formed are isolated. Methylene chloride, diisopropylether, ethyl acetate, trichloromethane, toluene, benzene or 1,4-dioxin may be used instead of acetic acid anhydride, while fuming 20 sulphuric acid, sulphur trioxide, chlorine sulphates or combinations thereof may be used as an alternative to conc. sulphuric acid. Synthesis of the naphthalene-1>sulphonic acid chlorides fllh: About 10 mmol of the naphthalene-1-sulphonic acids are combined successively 25 with 10 - 500 mmol, preferably about 90 mmol, of phosphorus oxytrichloride and 8 -50 mmol, preferably about 10 mmol, of phosphorus pentachloride and heated for 2 -16 h, preferably about 5 h, at 20 - 100°C, preferably by refluxing. Then the reaction mixture is evaporated down and combined with water. After extraction with organic diluent the combined organic extracts are dried and freed from solvent. The crude 30 product obtained is used in the subsequent steps without being purified. Instead of the phosphorus oxytrichloride/phosphorus pentachloride mixture, thionyl chloride, phosphorus pentachloride, a phosphoric acid/chlorine mixture or phosgene WO 02/100411 PCT/EP02/05338 9 may be used. The reaction may alternatively be carried out in the diluents ethyl acetate, water, acetonitrile, N,N-dimethylacetamide, sulpholane, DMF, hexane or dichloroethane. 5 Synthesis of the naphthalene-1-sulphonvl-amino-acetic acids: About 10 mmol of the chlorosulphonyl-naphthalenes, 10-100 mmol, preferably 11 -30 mmol, most preferably about 12 mmol, of aminoacetic acid and 10-100 mmol, preferably 11 - 30 mmol, most preferably about 12 mmol, of sodium hydroxide are dissolved in water and toluene. The reaction mixture is stirred for 2 -16 h at 0 -10 110°C, preferably at about 65°C, then the phases are separated. The aqueous phase is acidified and extracted. The combined organic extracts are dried and evaporated down. Purification may be carried out by chromatography. Triethylamine, potassium carbonate, sodium hydrogen carbonate or sodium hydride may be used instead of sodium hydroxide, while tetrahydrofuran, diethylether, 15 dichloromethane, trichloromethane, dioxin, acetone, benzene, ethanol, methanol, ethyl acetate or acetonitrile may be used instead of toluene. Cvclisation of the naphthalene-1-sulphonvl-amino-acetic acids (IV): About 10 mmol of the naphthalene-1-sulphonyl-amino-acetic acids are combined 20 with 10 - 200 g, preferably about 40 g, of polyphosphoric acid and stirred for 2 -16 h, preferably about 5 h, at 20 -110°C, preferably 75 - 95°C, most preferably at about 80°C. Then the reaction mixture is poured onto water and extracted. The combined organic extracts are dried and evaporated down. The residue is purified. WO 02/100411 PCT/EP02/05338 10 Method 2 Diagram 2 B (I") (V) (l) The compounds of formula (III) obtained as intermediate compounds in Method 1 are reacted with primary amines to obtain the compounds of formula (V) and then cyclised by the addition of a compound of formula R2R3C=0 in the presence of strong acid to obtain the target compounds (I). 10 In order to prepare the compounds of formula (I) wherein R1 and R2 represent hydrogen, paraformaldehyde, trioxane or formalin may be used and methanesulphonic acid, trifluoroacetic acid, sulphuric acid, phosphoric acid or polyphosphoric acid may be used as strong acids. 15 The general preparation of the compounds according to the invention in accordance with Diagram 2 is described in detail hereinafter. Synthesis of the naphthalene-sulohonamides (V): About 10 mmol of the chlorosulphonyl-naphthalenes (III) are combined with an 20 alcoholic solution of the primary amine (10 -1000 mmol in 5 - 200 ml, for example 200 mmol in 50 ml ethanol) and then heated to 0 -100 °C for 2 -16 h, preferably about 5 h, preferably by refluxing. Then the reaction mixture is evaporated down and purified. Instead of the alcoholic solvent it is also possible to use toluene, benzene, 25 trichloromethane, dichloromethane, diethylether, tetrahydrofuran, water, acetonitrile, acetic anhydride, acetone, pyridine, dimethylsulphoxide, dimethylformamide, dioxin or hexane. WO 02/100411 PCT/EP02/05338 11 Cvclisation of the naphthalene-1-sulphonamides N) to form the target compounds m. About 10 mmol of the naphthalene-1-sulphonamides are added to 0 -100 ml, 5 preferably 20 - 80 ml, most preferably about 40 ml of methanesulphonic acid and combined with a solution of 3 - 50 mmol, preferably 4-30 mmol, most preferably 5 mmol of trioxane in 0 -100 ml, preferably about 12 ml, of trifluoroacetic acid. The reaction mixture is stirred for 2 -16 h, preferably 5 h, at 20-100 C°, preferably 30 -80 °C, most preferably about 35°C and then poured onto ice water. After extraction 10 and drying of the combined organic extracts the solution is evaporated down. The crude product is purified. Instead of trioxane it is possible to use paraformaldehyde or formalin, while instead of trifluoroacetic acid it is possible to use boron trifluoride*diethylether, acetic acid, polyphosphoric acid, phosphoric acid or sulphuric acid. Acetic anhydride or 15 dichloromethane may be used as possible diluents. The new compounds of general formula (I) may be synthesised analogously to the following Examples of synthesis. These Examples are, however, intended solely as examples of procedure to illustrate the invention further without restricting it to the subject matter thereof. Synthesis of 2-methvl-2.3-dihvdro-naphthori.8-dein.31thiazine-1.1 -dioxide (Example 1): 2.21 g of N-methyl-1 -naphthalenesulphonic acid amide are dissolved in 25 ml of 25 methanesulphonic acid at 35°C and combined with a solution of 0.30 g of trioxane in 8 ml of trifluoroacetic acid. After 2 h stirring at ambient temperature The reaction mixture is poured onto-300 ml of ice water. The solid formed is separated off by filtration, washed with 100 ml of water and dried overnight. After crystallisation from methylcyclohexane the product is isolated as a white solid. Yield: 2.20 g. M.p.: 30 1 36°C. 10 WO 02/100411 PCT/EP02/05338 12 Synthesis of 6-chloro-2-methvl-2.3-dihvdro-naphthoH ,8-delM .3lthiazine-1.1 -dioxide (Example 2): 0.45 g of 5-chloro-naphthalene-1-sulphonic acid-N-methylamide are dissolved in 6.8 ml of methanesulphonic acid at 35°C and combined with a solution of 0.07 g of trioxane in 2 ml of trifluoroacetic acid. After 2 h stirring at 35°C The reaction mixture is poured onto 100 ml of ice water and the aqueous phase is extracted with ethyl acetate. The organic extracts collected are dried with sodium sulphate, evaporated down in vacuo and then purified by chromatography. Yield: 0.41 g. M.p.: 150°C. Synthesis of 2.3-dihvdro-naphthon.8-deiri.31thiazine- 1.1-dioxide (Example 3): Naphthalene-1-sulphonic acid tert-butylamide: 15 8 ml of tert. butylamine are placed in 50 ml of chloroform, cooled to 0° C and 5.75 g of 1-naphthalenic acid chloride in 45 ml of chloroform are added dropwise. Then the mixture is stirred for 24 h at ambient temperature. After concentration by evaporation in vacuo the residue obtained is dissolved in dichloromethane and washed with 2 N hydrochloric acid. The organic extracts collected are dried with sodium sulphate and 20 evaporated down in vacuo. Yield: 5.48 g. 2-tert-butyl-1,1 -dioxo-1,2-dihydro-1 X6-naphtho[1,8-de][1,3)thiazin-3-one; 4.36 g of naphthalene-1-sulphonic acid tert-butylamide are placed in 80 ml tetrahydrofuran, cooled to -10° C and 29 ml of N-butyl lithium (1.6 molar solution in 25 hexane) are cautiously added dropwise. The mixture is first stirred for 0.5 h at -10° C, then for 3 h at ambient temperature. Then it is cooled to -58 C and within 0.25 h C02 obtained from dry ice is piped in. The reaction mixture is stirred for 2.5 h at ambient temperature, then combined with water. The solution is poured onto 4 N hydrochloric acid and extracted with ethyl acetate. The organic extracts collected are 30 dried with sodium sulphate and after evaporation in vacuo purified by chromatography. Yield: 0.42 g. 2-tert-butyl-2,3-dihydro-naphtho[1,8-de][1,3]thiazine-1,1-dioxide: WO 02/100411 PCT/EP02/05338 13 0.17 g of 2-ferf-butyl-1,1 -dioxo-1,2-dihydro-1 X6-naphtho[1,8-de][1,3]thiazin-3-one are suspended in 2 ml tetrahydrofuran at ambient temperature, 1.17 ml of borane-tetrahydrofuran complex (1 molar Solution) are added. Then the mixture is refluxed with stirring for 100 h, with a total of a further 8.2 ml of 1M borane-tetrahydrofuran 5 complex solution being added in several batches. The reaction mixture is combined with 2 ml of 2 N hydrochloric acid and with 2 ml of methanol, then refluxed for 12 h with stirring. 2 ml of ammonia are added and any crystals formed are filtered off. The filtrate is extracted with ethyl acetate, the organic extracts collected are dried with sodium sulphate. After evaporation in vacuo the residue obtained is purified by 10 chromatography. Yield: 0.06 g. 2,3-Dihydro-naphtho[1,8-de][1,3]thiazine-1,1 -dioxide. 0.06 g of 2-fe/f-butyl-2,3-dihydro-naphtho[1,8-de][1,3]thiazin-1,1 -dioxide are dissolved in 1 ml of dichloromethane and 0.02 ml of trifluoroacetic acid are added. 15 Then the mixture is stirred for a total of 22 h at reflux temperature and for 96 h at ambient temperature, while during this period a total of 0.07 ml of trifluoroacetic acid are added. The reaction mixture is evaporated down in vacuo and purified by chromatography. Yield: 0.034 g. M.p.: 206<,-207° C. 20 Synthesis of r2-(1.1-dioxo-1H-3H-1A.6-naphthoH.8-delthiazine-2-vnethvlldimethvlamine (Example 4): 0.028 g of sodium hydride are suspended in 0.5 ml of dimethylformamide and 0.073 g of 2,3-dihydro-naphtho[1,8-de][1,3]thiazine-1,1-dioxide in 1 ml of 25 dimethylformamide are added. Then 0.053 g of diethylaminoethyl chloride-hydrochloride are added batchwise. The reaction mixture is stirred for 18 h at ambient temperature and then poured onto ice water. The mixture is extracted with dichloromethane and the organic extracts collected are dried with sodium sulphate. After evaporation in vacuo the residue obtained is purified by chromatography. 30 Yield: 0.035 g. M.p.: 97°-98°C. WO 02/100411 PCT/EP02/05338 14 Synthesis of N-f2-methvl-1.1 -dioxo-2.3-dihvdro-1 H-116-naphthor 1.8-dein.31thiazin-6-vn-acetamide: (Example 5): 5-acetylamino-naphthalene-1-sulphonylchloride: 5 1.40 g of 5-acetylamino-naphthalene-1 -sulphonic acid and 2.23 g of phosphorus pentachloride are combined and stirred for 4 h at 60° C. Then the solution is poured onto ice water and extracted with dichloromethane. The organic extracts collected are dried with sodium sulphate and evaporated down in vacuo. Yield: 1.10 g. 10 N-(5-methylsulphamoyl-naphthalene-1-yl)-acetamide: 1.10 g of 5-acetylamino-naphtha!ene-1 -sulphonyl chloride are dissolved in 8 ml of ethanol and 8 ml of methylamine solution in ethanol are added dropwise. Then the resulting mixture is stirred at reflux temperature for 3.5 h and the solvent is distilled 15 off in vacuo. The residue is purified by chromatography. Yield: 0.50 g. N-(2-methyl-1,1-dioxo-2,3-dihydro-1H-1X6-naphtho[1,8-de][1,3]thiazin-6-yl)-acetamide: 0.25 g of N-(5-methyIsulphamoyl-naphthalene-1-yl)-acetamide are dissolved in 3.4 20 ml of methanesulphonic acid at 35° C and combined with a solution of 0.027 g of trioxane in 1 ml of trifluoroacetic acid. After 6 h stirring at 35° C the reaction mixture is poured onto ice water and the aqueous phase extracted with ethyl acetate. The organic extracts collected are dried with sodium sulphate, evaporated down in vacuo and purified by chromatography. Yield: 0.136 g. M.p.: 189°-190° C. 25 Synthesis of 2-(1.1 -Dioxo-1 H .3H-1 X6-naphthor 1.8»de1 n .31thiazin-2-vn-acetamide: (Example 61: 8-tert-butylsulphamoyl-naphthalene-1 -carboxylic acid: 30 4.36 g of naphthalene-1-sulphonic acid ferf-butylamide are placed in 80 ml tetrahydrofuran, cooled to -10° C and 29 ml of N-butyl lithium (1.6 molar solution in hexane) are cautiously added dropwise. The mixture is stirred first for 0.5 h at -10°C, then for 3 h at ambient temperature. It is then cooled to -5°C and C02 obtained from dry ice is piped in within 0.25 h. The reaction mixture is stirred for 2.5 35 h at ambient temperature and then combined with water. The solution is poured onto 4 N hydrochloric acid and extracted with ethyl acetate. The organic extracts collected are dried with sodium sulphate and after evaporation in vacuo purified by chromatography. Yield: 1.19 g. WO 02/100411 PCT/EP02/05338 15 1,1 -Dioxo-1,1 -dihydro-1 \6-naphtho[1,8-de][1,3]thiazin-3-one: 0.25 g of polyphosphoric acid are taken and 0.15 g of 8-fe/f-butylsulphamoyl-naphthalene-1-carboxylic acid is added. The mixture is stirred for 4 h at 150°C. Then 5 the reaction mixture is poured onto ice water and the aqueous phase is extracted with ethyl acetate. The organic extracts collected are dried with sodium sulphate and evaporated down in vacuo. Yield: 0.07 g. 2,3-Dihydro-naphtho[1,8-de][1,3]thiazine-1,1 -dioxide: 10 0.07 g of 1,1-dioxo-1,1-dihydro-1 X6-naphtho[1,8-deJ[1,3]thiazin-3-one are dissolved in 2 ml of tetrahydrofuran and then 1.2 ml of 1 molar borane-tetrahydrofuran complex solution is carefully added dropwise. The mixture is stirred for 18 h at reflux temperature. The reaction mixture is combined with 1.5 ml of 2 N hydrochloric acid and 2 ml of methanol, then stirred for 2 h at reflux temperature. 2 ml of ammonia are 15 added and any crystals formed are filtered off. The filtrate is extracted with ethyl acetate, the organic extracts collected are dried with sodium sulphate and evaporated down in vacuo. Yield: 0.06 g. 2-(1,1 -Dioxo-1 H,3H-1 X6-naphtho[1,8-de][1,3]thiazin-2-yl)-acetamide: 20 0.011 g of sodium hydride are suspended in 0.5 ml of dimethylformamide, and 0.06 g of 2,3-dihydro-naphtho[1,8-de][1,3]thiazine-1,1-dioxide in 1 ml of dimethylformamide are added. The mixture is stirred for 1 h at ambient temperature and then 0.042 g of 2-bromoacetamide are added batchwise. Then the mixture is stirred for 18 h at ambient temperature. The reaction mixture is poured onto ice water and extracted 25 with dichloromethane. The organic extracts collected are dried with sodium sulphate and after evaporation in vacuo purified by chromatography. Yield: 0.043 g. M.p.: 195°-196° C. 30 Synthesis of 7-hvdroxv-2-methvl-2.3-dihvdro-naphthoH.8-deiri.3lthiazine-1.1-dioxide (Example 7k 0.6 g of 7-methoxy-2-methyl-2,3-dihydro-naphtho[1,8-de][1,3]thiazine-1,1 -dioxide are dissolved in 23 ml dichloromethane and the solution is cooled to -78° C. 2.3 ml of boron tribromide (1 molar solution in dichloromethane) are added dropwise. Then 35 the mixture is stirred for 24 h at ambient temperature. After evaporation in vacuo the residue is purified by chromatography. Yield: 0.36 g. M.p.: 245°-246° C. WO 02/100411 PCT/EP02/05338 16 Synthesis of methyl 2-methvl-1.1 -dioxo-2.3-dihvdro-1 H-1 X.s-naphthoH .8-delP1.3lthiazin-7-vl ester carboxvlate (Example 8): 0.11 g of 7-hydroxy-2-methyl-2,3-dihydro-naphtho[1,8-de][1,3]thiazine-1,1 -dioxide and 0.061 ml triethylamine are placed in 2 ml toluene and cooled to 0°C. 0.037 ml of methyl chloroformate are added dropwise. Then the mixture is stirred for 5 h at ambient temperature. The suspension is then poured onto ice water and extracted with ethyl acetate. The organic extracts collected are dried with sodium sulphate and, after evaporation in vacuo, purified by chromatography. Yield: 0.065g. M.p.: 161°-162°C. WO 02/100411 17 PCT/EP02/05338 The following compounds of formula IA are obtained, inter alia, analogously to the procedure described hereinbefore: 5 Table 1 Example R1 R2 R3 R4 R5 R6 Mp.[°C] 9 CH3 H H H H Br 226-227 10 CHa N02 H H H H 264-265 11 CHa H H OCHa H H 174-175 12 CHa H H F H H 129-130 13 CH3 H H Br H H 163-164 14 CHa H H CHa H H 142-143 15 CHa H H I H H 192-193 16 CHa H I H H H 160-161 17 CHa H no2 H H H 169-170 18 CHa H OH H H H 160-161 19 CHa N(CH3)2 H H H H 20 CHa H H H H N(CH3)2 21 CHa i-Pr H H iso-Pr H 22 CHa H OCOMe H H H 23 CHa H F H H H 10 It has been found that the compounds of general formula (I) are characterised by their wide range of applications in the therapeutic field. Particular mention should be WO 02/100411 PCT/EP02/05338 18 made of those applications in which the positive modulation of AMPA receptors plays a part. The effect of the compounds according to the invention as AMPA receptor modulators was measured electrophysiologically on cells which express functional 5 AMPA receptors. Investigations were carried out to see whether the test substances have a positive allosteric influence on the agonist-induced current. The test was carried out at concentrations of between 0.3 jamol and 300 jimol. 10 Table 2: Intensification of the agonist-induced current (+ good, ++ very good activity) Example Activity 1 + 2 ++ The new compounds can also be used to treat illnesses or conditions in which neuronal networks which require AMPA receptors in order to function are damaged 15 or limited in their function. The compounds of general formula (I) can thus be used in dementias, in neurodegenerative or psychotic illnesses and in neurodegenerative disorders and cerebral ischaemias of various origins, preferably in schizophrenia or learning an'd memory disorders. 20 The following are also included: epilepsy, hypoglycaemia, hypoxia, anoxia, cerebral trauma, brain oedema, amyotropic lateral sclerosis, Huntington's Disease, Alzheimer's disease, sexual dysfunction, disorders of sensory/motor function, memory formation, hyperkinetic behavioural changes (particularly in children), 25 hypotension, cardiac infarct, cerebral pressure (increased intracranial pressure), ischaemic and haemorrhagic stroke, global cerebral ischaemia on stoppage of the heart, acute and chronic neuropathic pain, diabetic polyneuropathy, tinnitus, perinatal asphyxia, psychosis, Parkinson's disease and depression, and related anxiety states. WO 02/100411 PCT/EP02/05338 19 The compounds of general formula I (and including naphtho[1,8-de]-2,3-dihydro-1,1-dioxide-1,2-thiazine) may also be given in conjunction with other active substances, such as those used for the same indications, or for example with neuroleptics, nootropics, psychostimulants, etc. They may be administered topically, orally, 5 transdermal^, nasally, parenterally or by inhalation. Moreover, the compounds of general formula I or the salts thereof may also be combined with active substances of other kinds. The compounds of general formula (I) (and including naphtho[1,8-de]-2,3-dihydro-10 1,1-dioxide-1-2-thiazine) may be given on their own or in conjunction with other active substances according to the invention, and possibly also in conjunction with other pharmacologically active substances. Suitable preparations include for example tablets, capsules, suppositories, solutions, - particularly solutions for injection (s.c., i.v., i.m.) and infusion - elixirs, emulsions or dispersible powders. The 15 content of the pharmaceutical^ active compound(s) should be in the range from 0.1 to 90 wt.-%, preferably 0.5 to 50 wt.-% of the composition as a whole, i.e. in amounts which are sufficient to achieve the dosage range specified below. Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium 20 phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers. 25 Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number of layers to achieve delayed 30 release, possibly using the excipients mentioned above for the tablets. Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, 2 0 jul 2005 | WO 02/100411 20 PCT/EP02/05338 cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanilline or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or 5 preservatives such as p-hydroxybenzoates. Solutions for injection and infusion are prepared in the usual way, e.g. with the addition of isotonic agents, preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, optionally using 10 emulsifiers and/or dispersants, whilst if water is used as the diluent, for example, organic solvents may optionally be used as solvating agents or dissolving aids, and transferred into injection vials or ampoules or infusion bottles. Capsules containing one or more active substances or combinations of active 15 substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules. Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof. Excipients which may be used include, for example, water, pharmaceutical^ 20 acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolins, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silicic acid and silicates), sugars (e.g. cane sugar, lactose and glucose) emulsifiers (e.g. lignin, spent sulphite 25 liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulphate). The preparations are administered by the usual methods, preferably by oral or transdermal route, particularly orally. For oral administration the tablets may of 30 course contain, apart from the abovementioned carriers, additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additives such as starch, preferably potato starch, gelatine and the like. Moreover, lubricants WO 02/100411 PCT/EP02/05338 21 such as magnesium stearate, sodium lauryl sulphate and talc may be used at the same time for the tabletting process. In the case of aqueous suspensions the active substances may be combined with various flavour enhancers or colourings in addition to the excipients mentioned above. 5 For parenteral use, solutions of the active substances with suitable liquid carriers may be used. The dosage for intravenous use is from 1 -1000 mg per hour, preferably between 5 and 500 mg per hour. 10 However, it may sometimes be necessary to depart from the amounts specified, depending on the body weight, the route of administration, the individual response to the drug, the nature of its formulation and the time or interval over which the drug is administered. Thus, in some cases it may be sufficient to use less than the minimum dose given above, whereas in other cases the upper limit may have to be exceeded. 15 When administering large amounts it may be advisable to divide them up into a number of smaller doses spread over the day. WO 02/100411 PCT/EP02/05338 22 The following examples of formulations illustrate the present invention without restricting its scope: Examples of Pharmaceutical Formulations 5 A) Tablets per Tablet active substance 100 mg lactose 140 mg 10 maize starch 240 mg polyvinylpyrrolidone 15 mg magnesium stearate 5 mg 500 mg 15 The finely-ground active substance, lactose and some of the maize starch are mixed together. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the remaining maize starch and the magnesium stearate are screened and mixed 20 together. The mixture is compressed to produce tablets of suitable shape and size. B) Tablets per Tablet active substance 80 mg 25 lactose 55 mg maize starch 190 mg microcrystalline cellulose 35 mg polyvinylpyrrolidone 15 mg sodium-carboxymethyl starch 23 mg 30 magnesium stearate 2 mg 400 mg </div>

Claims

<div class="application article clearfix printTableText" id="claims"> WO 02/100411 PCT/EP02/05338 23 The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate 5 which is dried and screened. The sodiumcarboxymethyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size. C) Ampoule solution 15 The active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic. The solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion. The ampoules contain 5 mg, 25 mg and 50 mg of active substance. 10 active substance sodium chloride aqua for inj. 50 mg 50 mg 5 ml WO 02/100411 PCT/EP02/05338 24 Patent Claims

1) A compound of general formula (I) wherein R1 denotes a group selected from among hydrogen, a Ci-C6-alkyl group optionally substituted by one or more halogen atoms, -S02H, -SC>2-Ci-C6-alkyl, -SO-Ci-C6-alkyl, -CO-Ci-C6-alkyl, -O, phenyl-Ci-C4-alkyl, -CrC4-alkyl-NR6R7 and -Ci-C4-alkyl-0- C1-C4-alkyl, and C3-C6-cycloalkyl, R2, R3, which may be identical or different, denote a group selected from among hydrogen, a Ci-C6-alkyl group optionally substituted by one or more halogen atoms, halogen, -NO2, -SO2H, -S02-C-i-C6-alkyl, -SO-Ci-C6-alkyl, -CO-Ci-C6-alkyl, -OH, -0-Ci-C6-alkyl, -S-Ci-C6-alkyl, -Ci-C4-alkyl-NR6R7 and -Ci-C4-alkyl-0- C1-C4 -alkyl and C3-C6-cycloalkyl, or R1 and R2 together denote a C4-C6-alkylene bridge, R6, R7, which may be identical or different, denote hydrogen, Ci-C4-alkyl or-CO-Ci-C4-alkyl, R4, which may be identical or different, denotes a group selected from among a CrC6-alkyl group optionally substituted by one or more halogen atoms, phenyl-CrC4-alkyl, halogen, -CN, -N02> -SO2H, -SO3H, -S02-Ci-C6-alkyl, -SO-Ci-C6-alkyl, -S02-NR6R7, -COOH, -CO-Ci-C6-alkyl, -0-C0-Ci-C4-alkyl, -C0-0-CrC4-alkyl, -0-C0-0-Ci-C4-alkyl, -CO-NR6R7, -OH, -0-Ci-C6-alkyl, -S-Ci-C6-alkyl, -NR6R7 and an aryl group optionally mono or polysubstituted by halogen atoms, -NO2, -SO2H or Ci-C4-alkyl, R5, which may be identical or different, denotes a group selected from among a Ci-C6-alkyl group optionally substituted by one or more halogen atoms, phenyl-Ci-C4-alkyl, halogen, -CN, -N02) -SO2H, -SO3H, -S02-Ci-C6-alkyl, -SO-CrCe-alkyl, -S02-NR6R7, -COOH, -CO-CrCe-alkyl, -0-C0-Ci-C4-alkyl, -C0-0-Ci-C4-alkyl, -0-C0-0-Ci-C4-alkyl, -CO-NR6R7, -OH, -0-Ci-C6-alkyl, l^tffii^rPROPERTY OFFICE N.Z. 2 0 JUL 2005 WO 02/100411 PCT/EP02/05338 25 -S-Ci-C6-alkyl, -NR6R7 and an aryl group optionally mono or polysubstituted by halogen atoms, -NO2, -SO2H or Ci-C4-alkyl, and n, m which may be identical or different represent 0, 1, 2 or 3, with the proviso that naphtho[1,8-de]-2,3-dihydro-1,1-dioxide-1,2-thiazine is excluded, optionally in the form of one or more of the various enantiomers and/or diastereomers thereof, or a pharmacologically acceptable salt thereof. 2) A compound of general formula (I) according to claim 1, wherein R1 denotes a group selected from among hydrogen, a CrC6-alkyl group optionally substituted by one or more halogen atoms, -SO2H, -S02-Ci-C6-alkyl, -SO-Ci-C6-alkyl, -CO-Ci-C6-alkyl, -O, -Ci-C4-alkyl-NR7R8 and -Ci-C4-alkyl-0- C1-C4 -alkyl, benzyl, R2, R3, which may be identical or different, denote a group selected from among hydrogen, a Ci-C6-alkyl group optionally substituted by one or more halogen atoms, halogen, -NO2, -SO2H, -SC>2-Ci-C6-alkyl, -SO-Ci-C6-alkyl, -CO-Ci-C6-alkyl, -OH, -0-Ci-C6-alkyl, -S-Ci-C6-alkyl, -Ci-C4-alkyl-NR6R7 and -Ci-C4-alkyl-0- CrC4 -alkyl, or R1 and R2 together denote a C4-C6-alkylene bridge, R6, R7 , which may be identical or different, denote hydrogen, Ci-C4-alkyl or -CO-Ci-C2-alkyl, and R4, which may be identical or different, denotes a group selected from among a Ci-C6-alkyl group optionally substituted by one or more halogen atoms, halogen, -CN, -N02i -SO2H, -SO3H, -COOH, -CO-Ci-C6-alkyl, -0-C0-Ci-C4-alkyl, -C0-0-Ci-C4-alkyl, -0-C0-0-Ci-C4-alkyl, -CO-NR6R7, -OH, -0-Ci-C6-alkyl, -S-CrC6-alkyl and -NR6R7, R5, which may be identical or different, denotes a group selected from among a CrC6-alkyl group optionally substituted by one or more halogen atoms, halogen, -CN, -N02, -SO2H, -SO3H, -COOH, -CO-Ci-C6-alkyl, -0-C0-Ci-C4-alkyl, -C0-0-Ci-C4-alkyl, -0-C0-0-Ci-C4-alkyl, -CO-NR6R7, -OH, -0-Ci-C6-alkyl, -S-Ci-C6-alkyl and -NR6R7, and intellectual property office :?F N.Z. 2 0 jul 2005 received WO 02/100411 26 n, m which may be identical or different represent 0,1 or 2, PCT/EP02/05338 optionally in the form of one or more of the various enantiomers and/or diastereomers thereof, or a pharmacologically acceptable salt thereof. 3) A compound of general formula (I) according to claim 1 or 2, wherein R1 denotes hydrogen, Ci-C4-alkyl or benzyl, R2, R3 which may be identical or different, denote hydrogen or Ci-C4-alkyl, or R1 and R2 together denote a butylene bridge, and R4, which may be identical or different, denotes a group selected from among a Ci-C6-alkyl group optionally substituted by one or more halogen atoms, halogen, -CN, -N02, -COOH, -CO-Ci-C6-alkyl, -0-C0-Ci-C4-alkyl, -C0-0-Ci-C4-alkyl, -0-C0-0-CrC4-alkyl, -CO-NR6R7, -OH, -O-CrCe-alkyl, -S-Ci-C6-alkyl and -NR6R7 R5, which may be identical or different, denotes a group selected from among a Ci-C6-alkyl group optionally substituted by one or more halogen atoms, halogen, -CN, -N02i -COOH, -CO-Ci-C6-alkyl, -0-C0-Ci-C4-alkyl, -C0-0-Ci-C4-alkyl, -0-C0-0-Ci-C4-alkyl, -CO-NR6R7, -OH, -0-Ci-C6-alkyl, -S-Ci-C6-alkyl and -NR6R7 and n, m which may be identical or different represent 0,1 or 2, optionally in the form of one or more of the various enantiomers and/or diastereomers thereof, or a pharmacologically acceptable salt thereof. 4) A compound of general formula (I) according to any one of claims 1 to 3, wherein R1, R2, R3, which may be identical or different, denote hydrogen or Ci-C4-alkyl, R4, which may be identical or different, denotes a group selected from among a Ci-C6-alkyl group optionally substituted by one or more halogen atoms, halogen, -N02, -0-C0-Ci-C4-alkyl, -0-C0-0-CrC4-alkyl, -0-Ci-C6-alkyl, and -NR6R7, R5, which may be identical or different, denotes a group selected from among a CrC6-alkyl group optionally substituted by one or more halogen atoms, halogen, -NO2, -0-C0-Ci-C4-alkyl, -0-C0-0-Ci-C4-alkyl, -0-Ci-C6-alkyl, and -NR6R7, and n, m which may be identical or different represent 0,1 or 2, INTELLECTLiAL PROPERTY Ut-flUt •}F N.Z. 2 0 JUL 2005 received WO 02/100411 PCT/EP02/05338 27 optionally in the form of one or more of the various enantiomers and/or diastereomers thereof, or a pharmacologically acceptable salt thereof. 5) A compound of general formula (I) according to any one of claims 1 to 4, wherein R1 denotes methyl, ethyl, i-propyl, n-butyl or benzyl, optionally in the form of one or more of the various enantiomers and/or diastereomers thereof, or a pharmacologically acceptable salt thereof. 6) A compound of general formula (I) according to any one of claims 1 to 5, wherein R1 denotes methyl, optionally in the form of a pharmacologically acceptable salt thereof. 7) A compound of general formula (I) according to claim 1, wherein R1 denotes methyl, R2, R3 denote hydrogen, R4, R5 which may be identical or different denote halogen, and n, m which may be identical or different represent 0,1 or 2, optionally in the form of a pharmacologically acceptable salt thereof. 8) Use of a compound of general formula (I) wherein R1 denotes a group selected from among hydrogen, a CrC6-alkyl group optionally substituted by one or more halogen atoms, -SO2H, -S02-Ci-C6-alkyl, INTELLECTUAL PROPERTY OFFICE N.Z. 2 0 JUL 2005 received WO 02/100411 PCT/EP02/0533 8 28 -SO-Ci-C6-alkyl, -CO-Ci-C6-alkyl, -O, phenyl-Ci-C4-alkyl, -Ci-C4-alkyl-NR6R7and -Ci-C4-alkyl-0- C1-C4-alkyl, and C3-C6-cycloalkyl, R2, R3, which may be identical or different, denote a group selected from among hydrogen, a Ci-C6-alkyl group optionally substituted by one or more halogen atoms, halogen, -N02, -S02H, -S02-Ci-C6-alkyl, -SO-Ci-C6-alkyl, -CO-Ci-C6-alkyl, -OH, -0-CrC6-alkyl, -S-Ci-C6-alkyl, -Ci-C4-alkyl-NR6R7 and -Ci-C4-alkyl-0- Ci-C4 -alkyl and C3-C6-cycloalkyl, or R1 and R2 together denote a C4-C6-alkylene bridge, R6, R7 , which may be identical or different, denote hydrogen, Ci-C4-alkyl or-CO-Ci-C4-alkyl, R4 , which may be identical or different, denotes a group selected from among a CrC6-alkyl group optionally substituted by one or more halogen atoms, phenyl-Ci-C4-alkyl, halogen, -CN, -N02, -S02H, -SO3H, -S02-Ci-C6-alkyl, -SO-Ci-C6-alkyl, -S02-NR6R7, -COOH, -CO-CrC6-alkyl, -0-C0-Ci-C4-alkyl, -C0-0-Ci-C4-alkyl, -0-C0-0-Ci-C4-alkyl, -CO-NR6R7, -OH, -0-Ci-C6-alkyl, -S-Ci-C6-alkyl, -NR6R7 and an aryl group optionally mono or polysubstituted by halogen atoms, -N02, -S02H or Ci-C4-alkyl, R5, which may be identical or different, denotes a group selected from among a Ci-C6-alkyl group optionally substituted by one or more halogen atoms, phenyl-Ci-C4-alkyl, halogen, -CN, -N02, -S02H, -SO3H, -S02-Ci-C6-alkyl, -SO-Ci-C6-alkyl, -S02-NR6R7, -COOH, -CO-Ci-C6-alkyl, -0-C0-C1-C4-alkyl, -C0-0-Ci-C4-alkyl, -0-C0-0-Ci-C4-alkyl, -CO-NR6R7, -OH, -0-Ci-C6-alkyl, -S-Ci-C6-alkyl, -NR6R7 and an aryl group optionally mono or polysubstituted by halogen atoms, -N02, -S02H or Ci-C4-alkyl, and n, m which may be identical or different represent 0, 1, 2 or 3, optionally in the form of one or more of the various enantiomers and/or diastereomers, or a pharmacologically acceptable salt thereof, for preparing a pharmaceutical composition for the treatment and/or prevention of neurodegenerative diseases and/or cerebral ischaemia of various origins. 9) Use of a compound of general formula (I) as defined in claim 8 for preparing a pharmaceutical composition for the treatment of schizophrenia. PROPERTY OFFICE ^ N.Z. 2 0 jul 2005 Dcrciwcn WO 02/100411 29 PCT/EP02/05338 10) Use of a compound of general formula (I) as defined in claim 8 for preparing a pharmaceutical composition for the treatment and/or prevention of memory disorders. 5 11) Use of a compound of general formula (I) as defined in claim 8 for preparing a pharmaceutical composition for the treatment of dementias. 12) Method of treating and/or preventing neurodegenerative diseases and/or cerebral 10 ischaemia in a non-human patient, characterised in that a patient is given an effective amount of a compound of formula (I) as defined in claim 8. 13) Method of treating and/or preventing schizophrenia, memory disorders and/or dementia in a non-human patient, characterised in that a patient is given an effective 15 amount of a compound of formula (I) as defined in claim 8. 14) A use or method as claimed in any of claims 8 to 13 wherein the compound of general formula (I) is as defined in claim 1. 20 15) A use or method as claimed in any of claims 8 to 13 wherein the compound of general formula (I) is as defined in claim 2. 16) A use or method as claimed in any of claims 8 to 13 wherein the compound of general formula (I) is as defined in claim 3. 25 17) A use or method as claimed in any of claims 8 to 13 wherein the compound of general formula (I) is as defined in claim 4. 18) A use or method as claimed in any of claims 8 to 13 wherein the compound of 30 general formula (I) is as defined in claim 5. 19) A use or method as claimed in any of claims 8 to 13 wherein the compound of general formula (I) is as defined in claim 6. : .-.ilK .. : hOPEBTY OFfiCE NX 2 0 jul 2005 WO

02/100411 PCT/EP02/05338 30 20) A use or method as claimed in any of claims 8 to 13 wherein the compound of general formula (I) is as defined in claim 7. 5 21) Pharmaceutical preparation containing as active substance one or more compounds of general formula (I) according to any one of claims 1 to 7 or a physiologically acceptable salt thereof in association with a pharmaceutically acceptable carrier, diluent or excipient. 10 22) A compound of general formula (I) as defined in claim 1, substantially as herein described with reference to any one of Examples 1 to 23. 23) A compound of general formula (I) according to any one of claims 1 to 7, substantially as herein described. 15 24) Use according to any one of claims 8 to 11 and 14 to 20, substantially as herein described with reference to any one of the Examples of Pharmaceutical formulations. 25) Use according to any one of claims 8 to 11 and 14 to 20, substantially as herein 20 described. 26) Method of any of claims 12 to 20, substantially as herein described. 27) Pharmaceutical preparation according to claim 21, substantially as herein described 25 with reference to any one or more of the Examples of Pharmaceutical Formulations. 28) Pharmaceutical preparation according to claim 21, substantially as herein described. PROPERTY OFFICE ■fF N.Z. 2 0 JUL 2005 received </div>